This company listing is no longer active
NeuBase Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Todd Branning
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.04% |
| Management average tenure | no data |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | n/a | n/a | -US$30m |
| Sep 30 2022 | US$922k | US$311k | -US$34m |
Compensation vs Market: Insufficient data to establish whether Todd's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Insufficient data to compare Todd's compensation with company performance.
CEO
Todd Branning (54 yo)
2.4yrs
Tenure
US$922,445
Compensation
Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.9yrs | US$1.15m | 6.14% € 78.5k | |
| Independent Chairperson | 4.9yrs | US$74.42k | 0.040% € 510.9 | |
| Independent Director | 4.9yrs | US$68.38k | 0.060% € 765.3 | |
| Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 4.7yrs | no data | no data | |
| Member of Gene Editing Advisory Board | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 3.6yrs | no data | no data | |
| Independent Director | 3.1yrs | US$59.79k | 0% € 0 |
3.6yrs
Average Tenure
57yo
Average Age
Experienced Board: O7P's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/02 22:04 |
| End of Day Share Price | 2024/05/13 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NeuBase Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Whitney Ijem | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |